熱門資訊> 正文
2022-01-07 20:00
06:59 AM EST, 01/07/2022 (MT Newswires) -- Nuvalent (NUVL) said Friday that the first patient has been dosed in the phase 1/2 clinical trial evaluating its NVL-520 lead product candidate in patients with advanced ROS1-positive non-small cell lung cancer and other advanced solid tumors.
According to the company, enrollment for the trial's phase-one dose-escalation portion is ongoing, with a view to evaluate the product candidate's safety and tolerability, and determine the recommended dosage for the phase-two trial.
Nuvalent said it also continues to advance the development of another drug, NVL-655, as a potential treatment for patients with ALK-positive non-small cell lung cancer.